93552-74-0

Upstream product

• 1694-31-1 tert-butyl acetoacetate 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 141-97-9 ethyl acetoacetate 

Downstream Products

• 134653-74-0 tert-Butyl 4-oxo-6-phenyl-4H-pyran-3-carboxylate 
• 2095486-67-0 3-(4-(((3S)-4-(4-bromobenzoyl)-3-(4-chlorophenyl)piperazin-1-yl)carbonyl)-5-methyl-1H-pyrazol-1-yl)benzonitrile 
• 186424-34-0 (R)-5-Methoxy-2-(4-methoxy-phenyl)-4,7-dioxo-6,7,8,8a-tetrahydro-4H,5H-chromene-4a-carboxylic acid tert-butyl ester 
• 186424-35-1 4a-(tert-Butoxycarbonyl)-2-phenyl-4a,7,8,8a-tetrahydro-4H-benzopyran-4,7-dione 
• 177348-97-9 tert-Butyl 4-oxo-6-(p-methoxyphenyl)-4H-pyran-3-carboxylate 

Relevant academic research and scientific papers

Stereocontrolled Synthesis of Kalihinol C

We report a concise chemical synthesis of kalihinol C via a possible biosynthetic intermediate, “protokalihinol”, which was targeted as a scaffold en route to antiplasmodial analogs. High stereocontrol of the kalihinol framework relies on a heterodendrale

Fused tricyclic compounds and application thereof in medicaments

The invention relates to fused tricyclic compounds and an application thereof in medicaments, and in particular to an application of the fused tricyclic compounds in medicaments for treating and/or preventing hepatitis B. In particular, the invention rela

FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE

The present invention relates to a fused tricyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the present invention relates to a compound having Formula (I) or

Fused tetracyclic compounds and application thereof in medicines

The invention relates to fused tetracyclic compounds and application thereof in medicines, in particular to application of the fused tetracyclic compounds as medicines for treating and/or preventing hepatitis B. Specifically, the present invention relates to compounds represented by a general formula (I) which is described in the specification or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, wherein all the variables are as defined in the specification. The invention further relates to application of the compounds as shown in the general formula (I) or the stereoisomers, the tautomers, the nitric oxides, the solvates, the metabolites, the pharmaceutically acceptable salts or the prodrugs of the compounds as medicines, particularly as medicines for treating and/or preventing hepatitis B.

Fused tricyclic compound and application in medicines

The invention relates to a condensed tricyclic compound and application in medicines, particularly to application of the condensed tricyclic compound as a medicine for treating and/or preventing hepatitis B. Specifically the present invention relates to a

NOVEL TRICYCLIC 4-PYRIDONE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the formula (I) wherein R1 to R7 are as described herein, compositions including the compounds and methods of using the compounds.

NOVEL 6,7-DIHYDROPYRIDO[2,1-A]PHTHALAZIN-2-ONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula: wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.

Pyrid-2-one derivatives and methods of use

Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Inotropic agents. Synthesis and structure-activity relationships of new milrinone related cAMP PDE III inhibitors

The synthesis of 6-substituted 5-acyl-1,2-dihydro-2-oxo-3-pyridinecarbonitriles 1b,c, 1,2,5,6,7,8-hexahydro-2,5-dioxo-3-quinolinecarbonitriles 1d-g and esters of 5-cyano-1,6-dihydro-2-methyl-6-oxo-3-pyridinecarboxylic acid 2b-e is described. In the case of le and If, a careful elucidation of the reaction mechanism is discussed. As milrinone analogues, the above compounds were tested on contractile activity and frequency rate of spontaneously beating atria from reserpine-treated guinea pigs. The methyl and tile benzyl esters 2b and 2e showed an appreciable positive inotropic activity when compared to milrinone. A fitting study with the DISCO (Distance Comparison) model has been carried out on 2e. This modeling approach allowed for the improvement of the pharmacophoric requirements for a better interaction with the cAMP-specific PDE (PDE III), thought to be the final biological target of these cardiotonic agents.

Synthesis and reactions of reduced flavones

The cycloadditions of a series of 4H-pyran-4-ones 3c-e with electron-rich dienes 11a,b to give reduced flavones 12 is described. The subsequent reactions of these reduced flavones with HCl, trifluoroacetic anhydride, ethyl anthranilate 19a and anthranilon